AVENUE THERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Avenue Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2017 to Q3 2024.
  • Avenue Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 40.2 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 40.2 +454 Sep 30, 2024
Q2 2024 159 +933 Jun 30, 2024
Q1 2024 -338 -843 -167% Mar 31, 2024
Q4 2023 -278 -374 -390% Dec 31, 2023
Q3 2023 -414 -459 -1019% Sep 30, 2023
Q2 2023 -774 -824 -1625% Jun 30, 2023
Q1 2023 505 +452 +851% Mar 31, 2023
Q4 2022 96 +52.1 +119% Dec 31, 2022
Q3 2022 45 -18.7 -29.4% Sep 30, 2022
Q2 2022 50.7 +11.5 +29.4% Jun 30, 2022
Q1 2022 53.1 +19.9 +60.1% Mar 31, 2022
Q4 2021 43.9 +17 +63.4% Dec 31, 2021
Q3 2021 63.8 +36.7 +136% Sep 30, 2021
Q2 2021 39.2 +17.6 +81.5% Jun 30, 2021
Q1 2021 33.2 +15.7 +89.4% Mar 31, 2021
Q4 2020 26.9 -1.83 -6.38% Dec 31, 2020
Q3 2020 27.1 -13 -32.5% Sep 30, 2020
Q2 2020 21.6 -30.1 -58.2% Jun 30, 2020
Q1 2020 17.5 -60.4 -77.5% Mar 31, 2020
Q4 2019 28.7 -80 -73.6% Dec 31, 2019
Q3 2019 40.1 -2.63 -6.16% Sep 30, 2019
Q2 2019 51.7 +25.6 +97.9% Jun 30, 2019
Q1 2019 77.9 +55.1 +242% Mar 31, 2019
Q4 2018 109 +73.9 +213% Dec 31, 2018
Q3 2018 42.7 -36.6 -46.2% Sep 30, 2018
Q2 2018 26.1 Jun 30, 2018
Q1 2018 22.8 Mar 31, 2018
Q4 2017 34.7 Dec 31, 2017
Q3 2017 79.3 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.